Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Cimzia® (certolizumab pegol) – New indication
September 13, 2024 - The FDA approved UCB’s Cimzia (certolizumab pegol), for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
